Brookdale Senior Living Inc.
HealthcareNYSE:BKD · New York Stock Exchange
+$0.49 today
Vol 2.99M · Avg 3.49M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
587.0%
avg 21.3%
ROIC
0.3%
avg -1.7%
ROA
-4.4%
avg -4.0%
Analysis
ROE is currently the strongest return metric at 587.0% versus its period average of 21.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Dawn L. Kussow | Executive Vice President & Chief Financial Officer | $1.89M | — | 52 | $486,476.00 | 0.20% |
Chad C. White | Executive Vice President, General Counsel & Secretary | $1.51M | — | 51 | $562,560.00 | 0.24% |
Nikolas W. Stengle | Chief Executive Officer & Director | $1.02M | — | 49 | $271,771.00 | 0.11% |
Mary Sue Patchett | Executive VP & COO | $912,729.00 | — | 63 | $60,123.00 | 0.03% |
Jaclyn C. Pritchett | Executive VP & Chief Human Resources Officer | $697,685.00 | — | 41 | $562,560.00 | 0.24% |
Ross C. Roadman | Senior Vice President | — | — | 75 | $562,560.00 | 0.24% |
Clark Jones | Senior Vice President of Strategic Operations | — | — | — | — | — |
David Cygan | Chief Marketing Officer | — | — | — | — | — |
Teddy Hillard | Senior Vice President of Corporate Development | — | — | — | — | — |
Camille Jordan | Senior VP & Chief Clinical Officer | — | — | — | $141,843.00 | 0.06% |
Tara Jones | Senior Vice President & Chief Information Officer | — | — | — | — | — |
Jessica Hazel | Vice President of Investor Relations | — | — | — | — | — |
Michael Grant | Vice President of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +20.1% | -2.0% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +20.1% over three years. Forward estimates point to Revenue at -2.0% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
National HealthCare Corporation
AMEX:NHC
$3.09B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
Acadia Healthcare Company, Inc.
NASDAQ:ACHC
$2.26B
89bio, Inc.
ETNB
$2.20B
Addus HomeCare Corporation
NASDAQ:ADUS
$1.74B
Aveanna Healthcare Holdings Inc.
NASDAQ:AVAH
$1.54B
Ardent Health Partners, LLC
NYSE:ARDT
$1.34B
Who manages BKD?
Brookdale Senior Living Inc. (BKD) lists 13 active executives. The top listed executive is Ross C. Roadman, Senior Vice President.
Are BKD insiders buying or selling?
Recent insider activity shows net selling of $12.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.